Synthesis and evaluation of novel potent HCV NS5A inhibitors

Synthesis and evaluation of novel potent HCV NS5A inhibitors Synthesis and evaluation of non-dimeric HCV NS5A inhibitors Potent Hepatitis C Virus NS5A Inhibitors Containing a Benzidine Core Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase 4-(1,1-Dioxo-1,4-dihydro-1λ6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase New potent biaryl sulfate-based hepatitis C virus inhibitors Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate Synthesis and evaluation of Janus type nucleosides as potential HCV NS5B polymerase inhibitors Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7′-substituents and initial pharmacokinetic assessments